The original success of Sildenafil undeniably transformed the medication landscape, but betting in companies strongly reliant on off-patent versions presents a challenging picture. Despite early returns were significant, the expiration of patents and the rise of cheaper alternatives have eroded sales. Therefore, a thorough evaluation of current fin